Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas-Looking Forward.

ABSTRACT: The cornerstone of therapy for primary retroperitoneal sarcomas (RPS) is complete surgical resection, best achieved by resecting the tumor en bloc with adherent structures even if not overtly infiltrated. Until recently, trials designed to elucidate the role of neoadjuvant radiation or chemotherapy for RPS have been unable to achieve sufficient enrollment. The completion of the STRASS trial, which explored neoadjuvant radiotherapy for primary resectable RPS, is a major milestone in RPS research, but has prompted further questions about histology-driven treatment paradigms for RPS. Though it was ultimately a negative trial with respect to its primary endpoint of abdominal recurrence-free survival, STRASS produced a signal that suggested improved abdominal recurrence-free survival with neoad

SUBMITTER: Istl AC 

PROVIDER: S-EPMC8998126 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature